Bristol Myers Squibb (CELG-RI) Capital Expenditures Growth (1y) (2010 - 2026)
Bristol Myers Squibb (CELG-RI) Capital Expenditures Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 26.65% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 19.70% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 16.88% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -3.02% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 22.41% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 39.02% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 30.84% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -13.75% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -28.86% |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | -15.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.51% |
| Mar 31, 2026 | 33.46% |
| Dec 31, 2025 | -2.12% |
| Sep 30, 2025 | -1.23% |
| Jun 30, 2025 | 37.79% |
| Mar 31, 2025 | -8.45% |
| Dec 31, 2024 | 14.55% |
| Sep 30, 2024 | -5.26% |
| Jun 30, 2024 | 1.16% |
| Mar 31, 2024 | 2.16% |
| Dec 31, 2023 | -4.62% |
| Sep 30, 2023 | 38.46% |
| Jun 30, 2023 | -4.78% |
| Mar 31, 2023 | 9.88% |
| Dec 31, 2022 | 8.13% |
| Sep 30, 2022 | -8.52% |
| Jun 30, 2022 | 29.52% |
| Mar 31, 2022 | 46.24% |
| Dec 31, 2021 | 13.07% |
| Sep 30, 2021 | 76.47% |